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Disrupted ERK1/2 (MAPK3/MAPK1) MAPK signaling has been as-
sociated with several developmental syndromes in humans; how-
ever, mutations in ERK1 or ERK2 have not been described. We
demonstrate haplo-insufficient ERK2 expression in patients with a
novel 1 Mb micro-deletion in distal 22q11.2, a region that in-
cludes ERK2. These patients exhibit conotruncal and craniofacial
anomalies that arise from perturbation of neural crest develop-
ment and exhibit defects comparable to the DiGeorge syndrome
spectrum. Remarkably, these defects are replicated in mice by
conditional inactivation of ERK2 in the developing neural crest.
Inactivation of upstream elements of the ERK cascade (B-Raf and
C-Raf, MEK1 and MEK2) or a downstream effector, the transcrip-
tion factor serum response factor resulted in analogous develop-
mental defects. Our findings demonstrate that mammalian neural
crest development is critically dependent on a RAF/MEK/ERK/
serum response factor signaling pathway and suggest that the
craniofacial and cardiac outflow tract defects observed in patients
with a distal 22q11.2 micro-deletion are explained by deficiencies
in neural crest autonomous ERK2 signaling.
22q11 microdeletion  human syndromes  MAP kinase
The ERK1/2 intracellular signal transduction pathway representsone of the principal signaling cascades mediating the transmis-
sion of signals from cell surface receptors to cytoplasmic and
nuclear effectors (1). ERK1/2 signaling is stimulated in response to
various extracellular factors, often through the activation of recep-
tor tyrosine kinases. The active receptors catalyze the assembly of
complexes of multiple adapter proteins linking the receptors to a
3-tiered protein kinase cascade comprised of Raf kinases (A-Raf,
B-Raf, C-Raf), MAP kinase kinases (MEK1/MEK2), and MAP
kinases (ERK1/ERK2). Important effectors of the ERK1/2 cascade
are transcription factors, including serum response factor (SRF),
which directs the expression of a broad range of genes through
interactions with the ternary complex factor family and myocardin-
related transcription factor (MTRF) families of transcription fac-
tors (2, 3).
A number of clinical syndromes result from mutations within
genes encoding proteins that are involved in the regulation of
ERK1/2 signaling (4). These include Noonan (Shp2/Ptpn11, K-Ras,
C-Raf, Sos1), LEOPARD (Shp2, K-Ras, C-Raf), Costello (H-Ras),
and Cardio-facio-cutaneous (B-Raf, H-Ras, MEK1, MEK2) syn-
dromes, which have been collectively termed neuro-cardio-facial-
cutaneous syndromes (NCFCS) (5). There is also evidence from
mouse models that suggests that ERK1/2 signaling may be dis-
rupted in DiGeorge syndrome (DGS)/velocardiofacial syndrome
(VCFS), the most common micro-deletion syndrome in humans
(one in 4,000 live births) (6). The majority of patients with DGS/
VCFS possess hemizygous deletions of proximal chromosome
22q11.2, most often encompassing a 3-Mb region that includes 35
genes (7, 8). Importantly, some of these genes (TBX1 and CRKL)
may act within a common genetic pathway that regulates ERK1/2
signaling (9).
The ERK2 (MAPK1) gene also localizes to chromosome 22q11,
but is positioned distal to and outside the 3-Mb DGS/VCFS region.
We have identified patients with de novo micro-deletions in distal
22q11.2 (10) by FISH, and cloned the breakpoints of the deletion
interval in patient 1 (11). The distal deletions include ERK2 as well
as several other genes and transcripts, many of which are related to
the Ig  light chain (IGLL) gene cluster (Fig. 1A). Within this set
of distal 22q11.2 genes, ERK2 represents an important candidate for
the etiology of the cardiac and craniofacial defects found in these
patients.
Patients with either typical or distal 22q11.2 deletions exhibit
defects in craniofacial and cardiac structures thought to be derived
from neural crest (10, 12, 13), a pluripotent cell population that
gives rise to and influences the development of a diverse array of
tissues in the developing embryo. These include numerous cranio-
facial structures, the cardiac outflow tract, and endocrine glands
(14). During development, neural crest cells are highly plastic and
are known to be dependent on cues from the extracellular envi-
ronment, such as sonic hedgehog, Wnts, bone morphogenetic
proteins, and FGFs (14). Nonetheless, our understanding of the
signal transduction pathways critical for neural crest development
is incomplete. In particular, the effects of conditionally eliminating
ERK1/2 signaling in developing neural crest has not previously been
investigated.
Here we show that patients with small 1 Mb, distal 22q11.2
micro-deletions exhibit haplo-insufficient ERK2 expression. To
explore the cell-specific role of ERK2 in these phenotypes, we
conditionally targeted components of the RAF/MEK/ERK path-
way in mice using floxed alleles and a Cre driver line that mediates
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robust recombination in neural crest. We have identified ERK2
isoform–specific effects on mouse cardiac and craniofacial devel-
opment that mimic defects observed in the haplo-insufficient
patients, indicating a likely role as the key gene mediating the
phenotype. Disruption of both ERK1 and ERK2 results in more
severe cardiac and craniofacial abnormalities, as well as thymic and
thyroid aplasia/hypoplasia. These effects are pheno-copied by the
conditional inactivation of the upstream ERK1/2 regulators, MEK1/
MEK2 and B-Raf/C-Raf, and remarkably by conditional inactivation
of a single downstream transcription factor, SRF. Our results show
that a Raf/MEK/ERK/SRF signaling pathway is necessary for
mammalian neural crest development. These data also demonstrate
a neural crest autonomous role for ERK2 signaling in developmen-
tal abnormalities associated with distal 22q11.2 micro-deletions.
Results
Patients with neural crest-related defects show haplo-insufficiency
for MAPK1/ERK2. We analyzed ERK2 expression in 3 patients with
heterozygous 22q11.2 micro-deletions mediated by low copy re-
peats distal to the DGS/VCFS region. Although patients with larger
deletions and similar phenotypes have been described, this cohort
represents deletions of the smallest region of overlap exhibiting the
full phenotype (10, 11, 13, 15) (Fig. 1A). The patients exhibit defects
within the DGS/VCFS spectrum including conotruncal cardiac
anomalies and craniofacial abnormalities, such as mandibular hy-
poplasia, bifid uvula, velopharyngeal incompetence, hypertelorism,
smooth philtrum, and ear anomalies (Fig. 1B). The conotruncal
cardiac defects in these patients are comparable to those seen in
DGS/VCFS. Notably, the anatomic malformations in our patients
are observed in neural crest-influenced or -derived structures.
The ERK2 gene is located within the distal 22q11.2 region and is
a strong candidate to underlie the etiology of the malformations
seen in these patients. Quantitative PCR and Western analysis of
peripheral blood and lymphoblastoid cell lines derived from pa-
tients with distal 22q11.2 deletions demonstrate a significant re-
duction of ERK2 mRNA and protein (Fig. 1 C and D), consistent
with ERK2 haplo-insufficiency in the patients. Importantly, the
protein level of TBX1, a critical gene located within the 3-Mb DGS
interval, was normal (Fig. 1D; n  2 distal 22q11 patients; n  4
normal controls). This suggests that the small deletion encompass-
ing ERK2 is not producing a cis-acting position effect on the DGS
region (Fig. 1D). Further, patients with a typical 3-Mb DGS 22q11.2
deletion and the same cardiac defect did not show decreased ERK2
protein levels, but did show decreased TBX1 expression consistent
with its hemizygosity in the common DGS deletion. Together, these
findings suggest that the related phenotypes result from the deletion
of distinct regions containing unique sets of genes. It is possible the
closely related ERK1 (MAPK3) isoform could contribute to these
phenotypes; however, no consistent change was noted in the protein
levels of ERK1 (MAPK3; Fig. 1D). Further, quantitative PCR did
not reveal any changes in ERK1 mRNA levels between distal
22q11-deleted cases and controls (data not shown). This is consis-
tent with the absence of ERK1 mutations in these patients following
sequencing of all exons and exon–intron junctions (S.C.S., unpub-
lished data). Thus, patients with distal 22q11 micro-deletions
exhibit ERK2 haplo-insufficiency and defects in neural crest-
derived structures.
Mouse Model of ERK2 Inactivation in Neural Crest. To explore the
role of ERK2 in the distal 22q11 micro-deletions and to further
dissect the role of MAPK signaling in neural crest development,
we used a mouse genetic approach. ERK2f lox/f lox mice were
generated by inserting loxP sites surrounding exon 3 of ERK2 and
mated with animals expressing a Wnt1:Cre transgene (16, 17),
resulting in ERK2 inactivation in the developing neural crest. We
also used ERK1/ mice to evaluate contributions by this related
isoform (18, 19).
Consistent with earlier reports, we found that Wnt1:Cre mediates
robust recombination in neural crest cells by E9.5 within the
pharyngeal arches, dorsal spinal cord, and dorsal root ganglion (20,
21) [supporting information (SI) Fig. S1A]. Analysis of later-stage
embryos revealed extensive recombination in all neural crest de-
rivatives including multiple craniofacial structures (Fig. S1B), the
cardiac outflow tract (Fig. 3M), and the peripheral and enteric
nervous system, in line with previous studies (16, 21). The dorsal



















*   Height below 3% for age and sex-matched growth curve
**  Head circumference below 3% for age and sex-matched normal growth curve
 

































































































Fig. 1. ERK2/MAPK1 protein and mRNA levels are decreased in patients with distal 22q11.2 deletions. (A) Deletions of chromosome 22q11.2 and their endpoints.
Chromosome-specific low copy repeats are designated A through F (not to scale). The distal deletions seen in the patients in this study occur in the 1-Mb interval
between low copy repeats (D and E). Relative locations of relevant genes are given. (B) Clinical findings in patients with distal micro-deletions of chromosome
22q11.2. (C) Gene expression plot from TaqMan assay of ERK2/MAPK1 is shown compared with 18s rRNA endogenous control. Error bars represent a composite
of 2 separate experiments run in triplicate. (D) Western blotting of lymphoblastoid samples revealed decreased ERK2, but not TBX1, in 2 different patients with
distal 22q11.2 micro-deletions compared with normal controls. Samples from a patient with DGS show decreased TBX1, but no change in ERK2.
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ERK2fl/fl Wnt1:Cre mice, exhibited significantly reduced expression
of ERK2 and the complete absence of ERK1 (Fig. S1C). These data
demonstrate that the ERK1/ ERK2fl/fl Wnt1:Cre mouse provides
a robust animal model for studying the conditional deletion of
ERK1/2 signaling during neural crest development in vivo.
ERK2 Signaling Is Necessary for the Development of Neural Crest-
Derived Craniofacial Structures In Vivo. We have reported previously
that the ERK1/ mice possess deletions in exon 1 through 6 and
express no detectable ERK1, but are viable and develop normally
(Fig. 2 A–F), presumably as a result of compensation by ERK2 (18,
19). Heterozygous conditional inactivation of ERK2 in neural crest
has no detectable effect on viability, and mice are born at expected
Mendelian frequencies (e.g., 22 of 76). However, in contrast to the
situation with ERK1, homozygous conditional inactivation of ERK2
in neural crest resulted in embryonic lethality with no viable
neonates detected (0 of 102). Although the expected ratio of
ERK2fl/fl Wnt1:Cre embryos was present in late gestation (8 of 28),
embryos exhibited a spectrum of major craniofacial defects includ-
ing a shortened maxilla, mandibular hypoplasia, and cleft palate
(Fig. 2 G-I; n  8). Many of these defects and the resulting cardiac
defects (as described later) resemble abnormalities noted in pa-
tients with distal 22q11 micro-deletions.
If ERK1 alleles were also deleted, craniofacial defects were
significantly exacerbated. ERK1/wt ERK2fl/fl Wnt1:Cre embryos
demonstrate more severe mandibular hypoplasia, maxillary trun-
cation, cleft palate, absence of the tongue, and eye placement
anomalies (Fig. 2 J-L; n  8 of 8). Homozygous inactivation of both
ERK1/2 genes (ERK1/ ERK2fl/fl Wnt1:Cre) resulted in more
robust truncation of the maxilla, mandibular aplasia, eye placement
anomalies, and absent tongue (Fig. 2 M-O; n  18 of 18). In
addition, these animals exhibited shortened crown–rump length
and absence of an external ear. We further analyzed the early effects
of ERK1/2 inactivation on the development of the pharyngeal
arches. In E10.5 ERK1/ ERK2fl/fl Wnt1:Cre embryos, but not
ERK2fl/fl Wnt1:Cre embryos, pharyngeal arch morphogenesis was
significantly hypoplastic compared with WT controls, suggesting a
defect in either neural crest migration or survival (Fig. S2 A–E).
These data demonstrate that the severity of the perturbations in
craniofacial development is regulated in a gene dose-dependent
manner by the expression of ERK1/2.
Elimination of ERK2 Signaling in Developing Neural Crest Leads to
Conotruncal Cardiac Defects. Conotruncal defects are typical in
DGS/VCFS, and are seen in patients with distal 22q11 micro-
deletions (10, 13, 15). Cardiac neural crest cells play an important
role in septation of the outflow tract and formation and remodeling
of the great arteries (16, 22). Crosses with the ROSA26 reporter
line further illustrate these contributions in the Wnt1:Cre mouse
heart (Fig. 3M) (20). A disruption in septa formation between the
aorta and pulmonary artery, valves, and outflow regions results in
persistent truncus arteriosus (PTA) and ventricular septal defects
(VSDs). ERK2fl/fl Wnt1:Cre embryos displayed variable pen-
etrance of these cardiac defects, with 2 of 5 embryos exhibiting
VSDs at E16.5, one of which also had PTA. One of 4 E17.5 animals
showed double-outlet right ventricle on gross dissection (Fig. 3
D–F). Thus, conditional elimination of ERK2 in developing neural
crest resulted in variable penetrance in abnormalities similar to
those observed in humans with distal 22q11 micro-deletions.
As with the craniofacial features, elimination of ERK1 alleles
exacerbated these effects. We consistently detect PTA and VSDs in
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Fig. 2. The development of craniofacial structures in mice is critically de-
pendent on ERK2 expression in neural crest. In comparison to E17.5 WT
embryos (A–C) ERK1/ embryos exhibit no significant defects (D–F). E17.5
ERK2fl/fl Wnt1:Cre embryos exhibit deficits in maxilla formation and mandib-
ular hypoplasia (G and H), cleft palate (I, arrow), and absence of the tongue.
Interestingly, ERK1/wt ERK2fl/fl Wnt1:Cre show more severe defects in cranio-
facial development (J–L). ERK1/ ERK2fl/fl Wnt1:Cre embryos exhibited the
most significant defects, including truncation of the maxilla (M and N),
mandibular aplasia (M and N), absence of an external ear (arrowhead in N),
overall decrease in crown–rump length, eye placement anomalies, and palatal
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Fig. 3. Disruption of ERK1/2 signaling results in cardiac outflow tract defects.
Compared with controls (A–C), ERK2fl/fl Wnt1:Cre embryos displayed variable
penetrance of cardiac outflow defects, including double-outlet right ventricle
(D), PTA (E), and VSDs (F). E16.5 cross-sections and dissected E17.5 embryos
(atria dissected away) from ERK1/wt ERK2fl/fl Wnt1:Cre (G–I) and ERK1/
ERK2fl/fl Wnt1:Cre (J–L) embryos consistently exhibited PTA and VSDs (I and L).
Whole-mount LacZ staining of Wnt1:Cre Rosa26LacZ hearts reveals the distri-
bution of neural crest derivatives in the embryonic conotruncus (M). Three-
dimensional reconstructions (N) of cross-sections from E16.5 control embryos
show a normal heart with 2 separate vessels, the aorta (red) and pulmonary
artery (light blue), connected distally by the ductus arteriosus. Cross-sectional
reconstructions of ERK1/ ERK2fl/fl Wnt1:Cre hearts further illustrate PTA in
these embryos (O). (ao  aorta, pa  pulmonary artery, rv  right ventricle,
lv  left ventricle, la  left atrium, ra  right atrium, da  ductus arteriosus.)











embryos, ERK1/ ERK2fl/fl Wnt1:Cre (n  5 of 5) embryos, and
dissected E17.5 hearts (Fig. 3 G–L). Three-dimensional reconstruc-
tions derived from the E16.5 cross-sections further illustrate PTA
in the ERK1/2-deficient animals (Fig. 3 N and O).
Thymus and Thyroid Abnormalities in the Absence of Neural Crest
ERK1/2 Signaling. Thymus and thyroid abnormalities are an impor-
tant element of the DGS/VCFS phenotypic spectrum, so these
tissues were examined. Compared with WT controls (Fig. S3 A–C),
the thymus and thyroid appeared morphologically normal in 4 of 5
E16.5 ERK2fl/fl Wnt1:Cre embryos evaluated by histology in cross-
sections, even though craniofacial defects were present (Fig. S3
D–F). This is consistent with the patient phenotypes, as those with
the recurrent small deletion that contains ERK2 have not been
shown to have significant glandular anomalies. In contrast,
ERK1/wt ERK2fl/fl Wnt1:Cre embryos possess a single-lobed, fused
thymus that is misplaced (Fig. S3G; n  6), whereas the thymus
failed to develop in ERK1/ ERK2fl/fl Wnt1:Cre embryos (Fig. S3J;
n  6). Additionally, the thyroid gland is misplaced and does not
develop normally in ERK1/wt ERK2fl/fl Wnt1:Cre and ERK1/
ERK2fl/fl Wnt1:Cre embryos. Instead of the normal bilateral lob-
ules, these embryos develop a medially localized, single-lobed
thyroid, identified by thyroglobulin expression (Fig. S3 H–L; n  3
of each). These results indicate that thyroid and thymus develop-
ment is dependent on ERK1/2 signaling in neural crest.
Inactivation of Upstream ERK1/2 Regulators Revealed a Conserved
Pathway. We sought to establish whether the phenotypic effects
arising from inactivation of ERK1/2 would be recapitulated upon
inactivation of upstream elements of the ERK1/2 cascade, including
those linked to NCFCS. Embryos in which both MEK1 and MEK2
were inactivated (MEK1fl/fl MEK2/ Wnt1:Cre) provided a nearly
exact phenocopy of ERK1/ ERK2fl/fl Wnt1:Cre embryos, exhib-
iting analogous craniofacial, heart, thymus, and thyroid defects
(Fig. 4; n  3 of 3). These animals exhibited late embryonic lethality
with mandibular hypoplasia and maxilla truncation, decreased
crown–rump length, and absence of the tongue and external ear
(Fig. 4 E and F). Cardiac defects were present, including fully
penetrant PTA and VSDs (Fig. 4 G and H), as well as thymus
aplasia and thyroid malpositioning (Fig. S3 M–O). No isoform
specific effects for MEK1 or MEK2 were identified, and defects
were only detected in embryos following homozygous inactivation
of both isoforms.
We also examined B-Raffl/fl C-Raffl/fl Wnt1:Cre embryos and
found that they exhibit mandibular and maxilla hypoplasia and
death in late gestation (Fig. 4 I and J). These defects are similar to
those seen in ERK1/wt ERK2fl/fl Wnt1:Cre or ERK2fl/fl Wnt1:Cre
embryos, in which the crown–rump length and external ear are
unaffected. This may be a result of an incomplete reduction in
ERK1/2 signaling resulting from compensation by the third Raf
isoform, A-Raf, which is also expressed in neural crest (23).
Outflow tract defects were of variable penetrance, and of the 6 mice
examined, 4 exhibited PTA and VSDs; one exhibited VSDs with a
DORV, but not overt PTA; and one was grossly normal (Fig. 4 K
and L). Thymus hypoplasia was observed in 5 of 8 E16.5/17.5
embryos whereas the thyroid was hypoplastic or malpositioned in
2 of 3 E16.5 embryos (Fig. S3 P and R).
SRF May Mediate the Effects of ERK1/2 Signaling on Neural Crest. The
SRF mediates some of the downstream effects of ERK1/2 on gene
expression through interactions with the ternary complex factor and
MTRF families. Remarkably, genetic inactivation of SRF in the
neural crest resulted in embryos that were phenotypically similar to
those in which ERK1/2 and its upstream regulators were inacti-
vated. SRFfl/fl Wnt1:Cre embryos died at late embryonic stages and
displayed fully penetrant mandibular hypoplasia (Fig. 5A), PTA
and VSDs (Fig. 5 D and E), and thymic and thyroid aplasia (Fig. S3
S–U; n  3). Maxillary hypoplasia was less severe and the external
ear and tongue were present, indicating that these developmental
aspects may be controlled by other downstream ERK1/2 effectors
(Fig. 5A). Thus, neural crest specific inactivation of this single
transcription factor results in craniofacial and cardiac defects
analogous to those seen in embryos in which ERK1/2 or its
upstream regulators were inactivated.
Discussion
Craniofacial and cardiac defects thought to arise principally from
perturbation of neural crest development are prominent features of
DGS/VCFS, which is caused by a recurrent deletion in chromosome
22q11 (12, 24). Significantly, deletions distal to the typical DGS/
VCFS region present with a similar spectrum of defects, including
cardiac outflow tract abnormalities, although different genes are
deleted (10, 12, 13). These distal hemizygous deletions include the
ERK2/MAPK1 gene (10), and we have shown here that deleted
patients show haplo-insufficiency for ERK2. We further demon-
strate that loss of ERK2 in mouse neural crest recapitulates many

























Fig. 4. Inactivation of upstream elements of the MAPK cascade results in
analogous defects in neural crest development. Compared with WT controls
(A–D), mandibular hypoplasia and maxillary truncation is observed in MEK1fl/fl
MEK2/ Wnt1:Cre E17.5 embryos (E and F). Disruption of MEK1/2 signaling
also resulted in decreased crown–rump length, eye placement anomalies,
absence of the tongue, and a disruption of external ear development (E and
F). PTA was consistently detected in E16.5 cross-sections and dissected E17.5
MEK1fl/fl MEK2/ Wnt1:Cre embryos (G and H). The conditional inactivation
of B-Raf/C-Raf did not alter embryonic size or external ear development, but
mandibular and maxilla hypoplasia (I and J) was observed. Analysis of B-Raffl/fl
C-Raffl/fl Wnt1:Cre embryos revealed partial penetrance of cardiac defects. An
E17.5 embryo is displayed (K) that clearly demonstrates PTA whereas cross-
sections from the E16.5 embryo (L) show mild conotruncal defects, namely
double-outlet right ventricle. Scale bars, 2 mm.
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and conotruncal defects. Our model organism analysis provides
support for a critical role for ERK2 in the pathogenesis of distal
22q11 micro-deletions, likely through the cell-autonomous disrup-
tion of neural crest development.
The distal 22q11/2 deletion contains other known genes and tran-
scripts includingHIC2,YPEL1,PPIL2,UBE2L3,SDF2L1, andPPM1F.
Immediately distal to this group of genes is the IGLL gene cluster.
Several genes including SUHW1 and 2, VPREB, TOP3B, and PRAME
are located within the IGLL locus. None of these genes has thus far
been associated with human disorders. We have sequenced the coding
regions of HIC2, YPEL, PPIL2, UBE2L3, PRAME, and MAPK1 in 25
patients with features of DGS/VCFS who do not show evidence of a
deletion in chromosome 22q, and also in another 20 patients with
isolated PTA. No potential pathogenic mutations were noted in these
cohorts (S.C.S., unpublished data).
Recent genetic analyses have shown that a number of syndromes
are associated with mutations in upstream elements of the ERK1/2
cascade (Fig. S4). In humans, these defects are typically recognized
as syndromes in the NCFCS spectrum. Mutations associated with
the NCFCS usually result in gain of function with respect to
signaling through ERK1/2, with the exception of certain LEOP-
ARD syndrome mutations in SHP2/PTPN11, which are associated
with loss of function (4, 25–30). Apparently, human cardiac and
craniofacial development is exquisitely sensitive to alterations in the
magnitude and dynamics of signaling through the ERK1/2 cascade.
Our data indicate a potential mechanistic link between the NCFCS
and DGS spectrum, via regulation of ERK1/2 activity in the
developing neural crest.
The development of the neural crest is known to be reliant upon
extracellular signals that may act through ERK1/2 signaling, par-
ticularly FGF8 (14). Mice in which the expression of FGF8 has been
reduced or eliminated exhibit defects similar to those noted in
ERK-inactivated mice, including cardiac defects involving PTA and
outflow tract anomalies, as well as mandibular hypoplasia and cleft
palate (31–34). Embryonic studies have shown a consistent corre-
lation between the spatial location of activated ERK1/2 and known
sites of FGF stimulation (35). FGF8 binding to FGF receptors
stimulates the ERK1/2 cascade by promoting the association of the
adapter proteins SHP2 and CRKL with activators of members of
the RAS family of small G-proteins. The mutation or inactivation
of SHP2 results in animals with severe cardiac defects and cranio-
facial abnormalities that are associated with dysregulation of
ERK1/2 activation (36–38). Inactivation of Crkl results in a very
similar phenotype (39). CRKL is positioned within the classical
recurrent DGS deletion, as is TBX1, which has been shown to
regulate the expression of FGF8 (40). Tbx1 mutant mice exhibit
more subtle craniofacial defects than those observed in the ERK1/2
inactivated mice, but the conotruncal defects are comparable (41).
Importantly, Fgf8 and Crkl interact within a common genetic
pathway critical for craniofacial and outflow tract morphogenesis
(6). Further, ERK1/2 activation is attenuated in the pharyngeal
epithelia in response to decreased Fgf8 and Crkl gene dosage (6).
These findings imply that the common developmental abnormali-
ties observed in individuals with the distal 22q11 deletion or with
the classical 3-Mb DGS deletion arise from perturbation of the
same pathway.
Our data show that ERK2 is required for normal neural crest
development. Whether the requirement for ERK2 represents an
isoform-specific effect or an effect on overall ERK1/2 activity is
unclear (42). Indeed, elimination of ERK1 alleles exacerbated
neural crest phenotypic defects. Of course, we cannot exclude
complex compensatory interactions between these 2 isoforms.
Importantly, conditional inactivation of MEK1/2 or B-Raf/C-Raf,
upstream canonical components of the ERK1/2 pathway, resulted
in near-identical developmental abnormalities in craniofacial and
conotruncal structures. Functions for RAF, MEK, or ERK outside
of the established signaling module have been identified; however,
the effects we have detected are consistent with their actions within
the ERK1/2 signaling cascade (43).
One of the remarkable outcomes of these studies is the discovery
that deletion of SRF in the developing neural crest results in
embryos that exhibit the same range of cardiac, craniofacial, and
glandular phenotypes as upstream elements of the pathway. SRF
forms dimeric complexes with the Ets family of ternary complex
factors, most prominently Elk1. Phosphorylation of Elk1 by
ERK1/2 results in the induction of expression of a number of genes
that regulate cell cycle and growth (44). Members of the MTRF
family also directly associate with SRF and act to regulate the
transcription of a large number of genes that participate in regu-
lation of the actin cytoskeleton. The most widely expressed member
of this family, MKL1, is phosphorylated by ERK1/2, which induces
gene expression (45, 46). Thus, SRF target genes are functionally
linked to the ability of cells to proliferate and migrate, consistent
with the phenotypes we have observed in embryos in which SRF
was conditionally deleted from neural crest. Our findings suggest
that SRF plays a dominant role in the regulation of ERK1/2-
dependent gene expression that governs neural crest development.
Conclusion
We have shown here that patients with distal 22q11 micro-deletions
are haplo-insufficient for human ERK2 expression. Elimination of
ERK2 specifically in mouse neural crest leads to craniofacial and
cardiac defects analogous to those seen in patients with ERK2
haplo-insufficiency, suggesting a neural crest autonomous role for
ERK2 signaling in the etiology of distal 22q11 micro-deletions.
Further genetic analysis demonstrated the importance of a Raf/
MEK/ERK/SRF pathway for mammalian neural crest develop-


























Fig. 5. Neural crest–specific inactivation of SRF disrupts mouse development.
E16.5 SRFfl/fl Wnt1:Cre embryos exhibit fully penetrant mandibular hypoplasia
(A, arrowhead). These embryos possess cardiac defects, including PTA (D) with
VSDs (E). Scale bars, 2 mm.











of DGS/VCFS, as well as the broad spectrum of NCFCS, may be
related to perturbation of a common genetic pathway necessary for
the activation of ERK1/2 (Fig. S4).
Experimental Procedures
Real-Time Expression Studies. Patients were ascertained as described previously
(10). Peripheral blood samples were collected from each patient after informed
consent, under an institutional review board-approved research protocol of the
Children’s Hospital of Philadelphia, and used to extract protein, DNA, and RNA,
andestablish lymphoblastoidcell lines.RNAwas isolatedfromcellsandcDNAwas
synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosys-
tems). Taqman (Hs00177066m1; Applied Biosystems) was performed in tripli-
cate for each sample toward a 127-bp amplicon spanning the boundary of exons
1 and 2 of MAPK1, and the endogenous control, 18s rRNA, by means of a relative
quantitation assay. Amplification reactions were performed as per the manufac-
turer’s instructions. All data were analyzed using the Applied Biosystems SDS-
7500 machine and SDS software version 1.4.
Western Blotting. Human lymphoblasts were collected in lysis buffer and equal
amounts of protein were separated in SDS/PAGE gels, and transferred to Immo-
bilon-P PVDF (Millipore). Membranes were blocked for 2 h at room temperature,
then incubated overnight at 4 °C with primary antibodies including mouse anti-
Erk2 (Becton Dickinson, 1:3,000), anti-Tbx1 (Lifespan Biosciences, 1:250), and
anti-G3PDH (Trevigen, 1:5,000). After rinsing, membranes were incubated with
secondary antibodies—HRP-conjugated goat anti-mouse or anti-rabbit antibody
(1:4,000;GEHealthcare)—in5%milk inbufferedsaline solution–Tween20for2h
atroomtemperature.Blotswerewashedwithbufferedsalinesolution–Tween20
and detection was performed using chemiluminescence reagents.
Transgenic Animals. All animal experiments were performed in accordance with
established protocols approved by the Institutional Animal Care and Use Com-
mittee at the University of North Carolina at Chapel Hill and mice were handled
in accordance with National Institutes of Health guidelines for the use and care
of laboratory animals. Mouse genotyping was performed by PCR using genomic
DNA isolated from tail samples collected at various stages. Primers used for gene
amplification and details regarding other transgenic mice in this work are de-
scribed in the SI Methods.
Histology and Immunohistochemistry. Embryos were fixed in 4% paraformalde-
hyde.Forcryoprotection,embryoswere incubated in30%sucrose/PBSsolutionat
4 °C for 2 to 3 days before embedding in Tissue-Tek OCT compound (Sakura
Finetek). Serial, transversesectionswerecollectedonSuperfrost/Plus slides (Fisher
Scientific). For general histological analysis, hematoxylin and eosin staining was
performed. For 3D reconstruction, images were collected, segmented into lu-
mens, and reconstructed with Amira. A surface smoothing algorithm was used
and the resulting 3D model was rendered as a surface. For immunofluorescence
microscopy, cryostat sections were incubated for 10 min in 0.1 M citrate buffer at
95 °C for antigen retrieval, incubated in polyclonal rabbit anti-human Thyroglob-
ulin (DakoCytomation), and diluted in blocking solution (PBS solution, 10%
normal goal serum, 0.5% Triton X-100) overnight at 4 °C. Following rinsing, slides
were incubated in 1:1,000 Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen)
in blocking solution for 2 h at room temperature and mounted.
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